The handle http://hdl.handle.net/1887/54687 holds various files of this Leiden University dissertation

Author: Broekman, Winifred
Title: Mesenchymal stromal cell treatment for COPD : experimental and clinical studies
Issue Date: 2017-09-07
FUNCTIONAL CHARACTERIZATION OF BONE MARROW-DERIVED MESENCHYMAL Stromal CELLS FROM COPD Patients

CHAPTER 4
ABSTRACT

Autologous bone marrow-derived mesenchymal stromal cells (BM-MSCs) are evaluated for clinical use in COPD patients, but it is unclear whether COPD affects BM-MSCs.

To investigate this, BM-MSCs from 9 COPD patients and 9 non-COPD age-matched controls were compared in immunophenotype, growth and differentiation potential, and migration capacity. Other functional assays included the response to proinflammatory stimuli and inducers of the Nrf2 antioxidant response element (Nrf2-ARE) pathway, and effects on NCI-H292 airway epithelial cells.

No significant differences were observed in morphology, proliferation and migration, except for increased adipocyte differentiation potential in the COPD group. Both groups were comparable regarding mRNA expression of growth factors and inflammatory mediators, and in their potential to induce mRNA expression of EGFR ligands in NCI-H292. MSCs from COPD patients secreted more IL-6 in response to proinflammatory stimuli. Activation of the Nrf2-ARE pathway resulted in a comparable induction of mRNA expression of 4 target genes, but the expression of NQO1 was lower in MSCs from COPD patients.

The observation that MSCs from COPD patients are phenotypically and functionally comparable to those from non-COPD controls implies that autologous MSCs can be considered for use in the setting of clinical trials as a treatment for COPD.
INTRODUCTION

Mesenchymal stromal cells (MSCs) are defined as plastic adherent cells with the capacity to self-renew and differentiate into multiple lineages of the mesenchyme [1]. Importantly, it has been shown that MSCs stimulate recovery of damaged tissue via paracrine effects, potentiation of cell growth and wound healing, suppression of apoptosis and possibly induction of endogenous progenitor cell potential [2]. In addition to their regenerative potential, MSCs have pleiotropic effects on several immune cells and can contribute to immune responses by modifying the inflammatory environment [3].

In light of these regenerative and immunomodulatory properties of MSCs, interest has arisen in the clinical application of MSCs as a treatment for chronic obstructive pulmonary disease (COPD). COPD is a heterogeneous disease, defined by persistent airflow limitation that is usually progressive. Mechanisms that contribute to COPD development include exaggerated inflammatory responses to inhaled noxious gases, imbalance between proteinases and proteinase inhibitors, and excessive oxidative stress [4]. On a cellular level, an imbalance of cell death and replenishment of structural cells ultimately results in tissue damage.

In COPD, MSC-based treatments have already been used in the context of clinical trials investigating both allogeneic [5] and autologous MSCs (ClinicalTrials.gov NCT01306513). A concern when using MSCs is that donor-related factors might affect the therapeutic potential of MSCs. This is conceivable in MSCs from COPD patients, since COPD is considered to have a systemic component [6]. Indeed, in a preliminary report by Jahn et al, functional differences between MSCs from COPD and control patients were observed [7]. Alternatively, it has been hypothesized that altered MSC function contributes to the development of COPD [8].

Since autologous MSCs are currently used in clinical trials to evaluate their ability to induce (favourable) responses in lung tissue, it is relevant to know whether MSCs from COPD patients have similar properties and potential as MSCs from healthy donors. In this study this was investigated using in vitro cultures of bone marrow-derived MSCs (BM-MSCs) from COPD patients and age-matched non-COPD controls. We compared the MSC (immuno)phenotype and several functional parameters, including differentiation and migration, response to proinflammatory stimuli and inducers of the Nuclear factor (erythroid derived 2)-like 2 antioxidant response element (Nrf2-ARE) pathway, and regenerative effects on airway epithelial cells.

MATERIALS AND METHODS

A more detailed description of the methods used for this study is provided in an online supplement, available via ERJ Open Research.
Patients and ethical considerations
BM-MSCs were obtained from COPD patients participating in a clinical trial to evaluate BM-MSCs for severe emphysema (ClinicalTrials.gov NCT01306513), and from non-COPD controls [9]. Groups were matched for age (COPD 53.1 ± 6.4 years [mean ± SD] versus non-COPD 48.8 ± 4.5; p=0.12) and sex (both groups 3 males out of 9). The control group included 1 Asian donor, all others were Caucasian. COPD donors had FEV$_1$ < 40% predicted, emphysema on CT-scan, and had quit smoking at least 6 months prior to bone marrow aspiration. Controls had no known pulmonary disease, and were never smokers (the smoking history of three controls could not be traced). The use of MSCs for preclinical research was approved by the Medical Ethical Committee of the Leiden University Medical Center, and donors consented to the possible use of their MSCs for this purpose.

MSC cultures and characterization
MSC isolation from bone marrow and expansion in vitro was done following a previously published protocol [10], monitoring expansion rates during initial cultures. MSC immunophenotype was confirmed by FACS analysis, differentiation potential was quantified by measuring adipocyte, osteoblast and calcium staining intensity of differentiated MSCs, and migration was assessed using Electric Cell-substrate Impedance Sensing (ECIS). MSCs at passage three or four were used for experiments, after overnight incubation in serum-free (SF) medium.

Stimuli
Cigarette smoke extract (CSE) and sulforaphane were used to induce the Nrf2-ARE pathway [11-13]. Tumor Necrosis Factor-α (TNF-α) and Interleukin-1β (IL-1β) (Peprotech, Rocky Hill, NJ, USA) at 20 ng/ml were used as proinflammatory stimuli to evaluate immune modulatory properties and growth factor induction. MSC-conditioned medium was generated by culturing MSCs during 24 hours in SF medium, or in SF medium supplemented with TNF-α/IL-1β and was used to stimulate NCI-H292 airway epithelial cells.

qPCR and ELISA
MSCs were stimulated during 6 hours for quantitative real-time PCR (qPCR) analysis, or during 24 hours for ELISAs. NCI-H292 airway epithelial cells were incubated during 9 hours with MSC-CM to assess induction of mRNA expression of EGFR-ligands. Following RNA extraction and cDNA synthesis, qPCR was performed in triplicate using primers for target genes (supplementary Table S1), and relative gene expression compared to reference genes was calculated according to the standard curve method, with housekeeping genes selected based on Genorm software [14], i.e. B2M and RPS29 for MSCs and ATP5B and RPL13A for NCI-H292. IL-6 (Sanquin, Amsterdam, the Netherlands) and IL-8 (R&D Systems, Minneapolis, MN, USA respectively) secretion was measured using ELISA, following the manufacturer’s protocol. Optical density values were measured with a microplate reader.
Statistical analysis
Data analysis and composition of the figures was done using GraphPad Prism 6.0 (GraphPad Software Inc., La Jolla, CA, USA) and SPSS 20 (IBM SPSS Statistics, Armonk, NY, USA). Statistical analysis was performed using Mann-Whitney U-test for analysis of differences between subject groups or Wilcoxon matched pairs signed rank test for paired observations to compare conditions within groups. Differences were considered statistically significant at p<0.05.

RESULTS

BM-MSCs from COPD patients have the same (immune)phenotype as non-COPD controls, apart from a stronger potential towards adipocyte differentiation
BM-MSCs from COPD patients and non-COPD controls were morphologically similar, displaying the characteristic spindle-shaped appearance (Figure 1A). No differences were observed in immunophenotype (Figure 1B) and all MSCs could be differentiated into adipocytes and osteoblasts, confirming their MSC phenotype. MSCs from COPD donors showed a significantly higher potential to differentiate into adipocytes than MSCs from non-COPD donors (Figure 1C). No significant differences were observed in osteoblast differentiation and mineralization potential. In 6 patients (4 in the non-COPD group, 2 in the COPD group), no data were obtained for osteoblast differentiation, mineralization or both, due to ruptures and subsequent detachment of the monolayer, caused by contractility of cells at the periphery of the well during differentiation.

Proliferation and migration potential of MSCs is not affected in MSCs from COPD patients
Proliferation was assessed during expansion following initial isolation from bone marrow. No differences were observed between groups regarding the time between passages, and the number of MSCs harvested per passage (Figure 2A). Migration was assessed as the potential of MSCs to cover the surface area of an electrode using ECIS analysis to measure resistance and capacitance. This showed that the migration potential of MSCs from COPD patients was similar to that of non-COPD controls (Figure 2B).
Figure 1. MSCs phenotype from COPD and non-COPD patients. Bone marrow-derived MSCs from COPD and non-COPD patients cultured in vitro were characterized by FACS analysis and by their potential to differentiate into mesenchymal lineages. (A) Morphology of MSCs from COPD and non-COPD donors: example of MSC culture. (B) FACS data. Per antibody, data are shown as mean ± SEM (n=9 per group). (C) Differentiation into adipocytes and osteoblasts, and mineralization potential. Staining intensity of oil red O, alkaline phosphatase and alizarin red (calcium) was quantified on a microplate reader, and per donor OD-values were calculated as fold change compared to its control (co-cultured undifferentiated MSCs). Box whiskers represent median, interquartile range and minimum and maximum values. * p < 0.05 for n = 9 per group (for osteoblast/mineralization 6-8 donors/group).
Figure 2. MSC proliferation and migration capacity. (A) In vitro proliferation of MSCs from COPD and non-COPD patients was followed over time. Time needed for cultures to become near-confluent and the number of MSCs that were obtained per passage were assessed. Population doubling time (PDT) in days was calculated by dividing the natural logarithm of 2 by the exponent of growth. Box whiskers represent median and interquartile range, minimum and maximum values. (B) Migration as assessed using ECIS. MSCs were cultured in ECIS arrays in the presence of an electrical fence (EF), which prevented cell adherence across the electrode area. Resistance (at 500 Hz) and capacitance (at 40 kHz) were measured continuously and followed up to 15 hours after removal of the electrical fence (at time = 0). Restoration of the resistance and capacitance to control values (corresponding to full coverage of the electrode) was used as a measure for migration capacity of MSCs. Normalized (nlz) data were obtained by correcting for the resistance/capacitance values obtained in control wells without an electric fence, at the time the electric fence was removed. Data are shown as mean ± SEM. n = 5-8 per group.
BM-MSCs’ response to proinflammatory stimuli is similar between groups, except for higher IL-6 secretion in MSCs from COPD patients

Previously, MSCs were shown to express growth factors and immune mediators upon exposure to proinflammatory stimuli [15,16]. We therefore investigated whether this response was preserved in MSCs from COPD patients. In MSCs from COPD patients as well as non-COPD controls, incubation with TNF-α and IL-1β resulted in a significant induction of gene expression of Amphiregulin (AREG), Heparin-binding Epidermal Growth Factor like Growth Factor (HBEGF), Fibroblast Growth factor 2 (FGF2), Chemokine (C-C motif) ligand 20 (CCL20), Interleukin 6 (IL6), Chemokine (C-X-C motif) ligand 8 (CXCL8) and Tumor necrosis factor-Stimulated Gene 6 (TSG6) in both the COPD and non-COPD group (Figure 3A). Furthermore, it increased Transforming growth factor-α (TGFA) in the non-COPD group, and hepatocyte growth factor (HGF) in the COPD group (data not shown), and lowered expression of Adrenomedullin (ADM1) in both groups (Figure 3A). Between groups, no significant differences were observed. No significant induction was observed for other genes investigated (Supplementary Figure S1).

IL-6 and IL-8 protein secretion was measured in medium obtained from TNF-α and IL-1β exposed MSCs. In unstimulated MSCs, IL-8 levels were below the detection limit, and IL-6 secretion was comparable between groups (164 ± 27.7 pg/ml [mean ± SEM] for COPD, versus 174 ± 31.6 pg/ml in non-COPD, p=0.34). Upon stimulation with proinflammatory cytokines, IL-8 and IL-6 secretion significantly increased in MSCs from both COPD and non-COPD donors. Differences between groups were observed, as MSCs from COPD patients secreted significantly higher amounts of IL-6, and showed a trend towards higher IL-8 secretion (p=0.12) (Figure 3B).

Oxidative stress response in MSCs from COPD patients is comparable to non-COPD MSCs

In COPD, insufficient antioxidant response has been implicated in disease pathogenesis [17]. Therefore, we evaluated the antioxidant response of MSCs from COPD patients, using CSE and sulforaphane to activate the Nrf2-ARE pathway and assessed induction of several downstream target genes involved in antioxidant response [11-13]. In both groups, incubation of MSCs with CSE resulted in a significant induction of heme oxygenase 1 (HMOX1), NAD(P)H:quinone reductase 1 (NQO1) and smoke and cancer-associated IncRNA-1 (SCAL1). For HMOX1 and SCAL1, this induction was dose dependent. Glutathion peroxidase 2 (GPX2) expression decreased in CSE exposed MSCs. Induced gene expression of NQO1 and SCAL1 was generally lower in MSCs from COPD patients, resulting in significant differences between groups in NQO1 expression at higher concentrations of CSE (Figure 4A).

Sulforaphane significantly increased all analysed Nrf2-ARE regulated target genes in non-COPD patients, whereas it only significantly induced HMOX1 and SCAL1 gene expression in MSCs from COPD patients (Figure 4B). Despite this observation, groups did not significantly differ from each other in their response to sulforaphane.
Figure 3. Induction of immune mediators and growth factors upon stimulation with proinflammatory cytokines. MSCs were stimulated with TNF-α and IL-1β (20 ng/ml each) or control medium (NC) during 6 hours. (A) mRNA expression of immune mediators and growth factors, normalized for housekeeping genes, shown for COPD (circles) and non-COPD donors (squares). Individual data are shown in graphs, horizontal bars represent mean. * p < 0.05 for n = 9 per group. (B) IL-6 and IL-8 protein secretion by MSCs from COPD and non-COPD donors, assessed 24 hours after addition of TNF-α and IL-1β. Individual data points are shown, horizontal bars represent mean. * = p < 0.05 for n = 9 per group.
Figure 4. Induction of Nrf2-ARE target genes in MSCs from COPD and non-COPD donors. Gene expression of GPX2, HMOX1, NQO1 and SCAL1 was assessed in MSCs from COPD and non-COPD donors 6 hours after addition of cigarette smoke extract (CSE) or sulforaphane (SFN), which are both inducers of the Nrf2-ARE pathway, or plain culture medium as a negative control (NC). (A) Normalized mRNA expression in response to increasing concentrations of CSE. Data are presented as mean ± SEM. * p < 0.05 for n = 9 per group (except CSE 1.0 AU/ml: n = 7 in COPD group). (B) Normalized mRNA expression in response to 25 μM SFN, compared to housekeeping genes. Individual data are shown, with mean represented by the horizontal bar. * p < 0.05 for n = 9 per group.

The regenerative potential of MSCs from COPD patients is comparable to non-COPD MSCs. MSC conditioned medium (MSC-CM) from healthy donors induced EGFR ligand expression in NCI-H292 airway epithelial cells [15]. We assessed if MSC-CM from COPD patients has the same regenerative potential by investigating induction of mRNA expression of EGFR ligands in NCI-H292 airway epithelial cells, following incubation with MSC-CMCTRL (from MSCs cultured in SF medium) or MSC-CMSTM (from MSCs cultured in SF medium supplemented with TNF-α/IL-1β). Compared to control culture medium, both MSC-CMCTRL as well as MSC-CMSTM induced gene expression of the EGFR ligands AREG and HBEGF and to a lesser extent of TGFA (data not shown).
in NCI-H292. In addition, both MSC-CM<sup>CTRL</sup> and MSC-CM<sup>STIM</sup> induced mRNA expression of the cell cycle regulator Cyclin D1 (CCDN1), that is considered as a marker for cell proliferation. Compared to MSC-CM<sup>CTRL</sup> no significant differences were observed between the COPD and non-COPD groups in the potential of MSC-CM<sup>STIM</sup> to induce EGFR ligands in NCI-H292 airway epithelial cells, although there were differences in the significance of effects of MSC-CM<sup>STIM</sup> from non-COPD and COPD patients (Figure 5).

**DISCUSSION**

In this study we show that MSCs from patients with COPD are largely comparable in phenotype and function to MSCs from non-COPD controls. MSCs from COPD patients responded similarly to those from non-COPD controls for the majority of the investigated parameters, including (immuno) phenotype, proliferation and migration potential, response to proinflammatory stimuli and effects on airway epithelial cells. However, we did observe differences in adipocyte differentiation, IL-6 secretion in response to proinflammatory stimuli, and induction of gene expression of NQO1 upon stimulation of the Nrf2-ARE pathway. These observations have important implications for the use of autologous MSCs as a potential new therapy to treat COPD.

This is the first study in humans that investigates whether MSCs from COPD patients are comparable to those from healthy controls. Our observation that underlying COPD does not appear to affect MSC function is in line with previous observations made in chronic systemic diseases [18-21]. In contrast, altered MSC function was observed in MSCs from patients with disorders of the central nervous system [22,23], and altered MSCs growth and differentiation has been observed in hematologic diseases [24,25]. Possibly, these differences might relate to the affected organ of the underlying disease, which is especially conceivable for diseases originating from the bone marrow.
MSCs secrete a spectrum of soluble factors, including cytokines, chemokines and growth factors [2,3], and it was shown that this secretion differs depending on for instance site of origin of MSCs, or systemic conditions such as hypoxemia [26,27]. Likewise, a proinflammatory environment can ‘activate’ MSCs, as proinflammatory cytokines were shown to induce expression of immune mediators and trophic factors in MSCs (reviewed in [16]). We used the proinflammatory cytokines TNF-α and IL-1β that are implicated in COPD pathogenesis [28,29] and likewise observed induction of immune mediators and growth factors, which was unaffected by COPD status. Along with the observation that MSC-CM-induced EGFR ligand expression in airway epithelial cells was comparable between groups, these data provide evidence that MSCs from COPD patients respond in a similar fashion to inflammation. This suggests that their ability to modify inflammation and induce repair upon recruitment to inflammatory sites, such as the lung in COPD, is preserved.

MSCs from COPD and non-COPD donors were phenotypically similar and all had trilineage differentiation potential, confirming their status as progenitor cells. We found significantly higher adipocyte differentiation in MSCs from COPD patients compared to their healthy counterparts and a trend towards lower osteogenic differentiation. Our data might have even underestimated the osteogenic differentiation potential of MSCs from the non-COPD group, due to loss of the differentiated monolayer due to strong contractility of differentiated cells at the wells periphery, in a substantial subgroup of COPD and non-COPD subjects. Similar to MSCs from COPD patients, increased adipocyte differentiation has been observed in aged MSCs and this appears to occur at the expense of osteoblast differentiation [30-32]. A definite statement about this so called “adipogenic switch” in aged MSCs has not yet been made due to inconsistencies between studies [33]. However, if cellular ageing affects the differentiation potential of MSCs, then based on the current data we propose that increased cellular ageing may underly the “adipogenic-switch” we observed in MSCs from COPD patients. Interestingly, accelerated cellular ageing has been thought to underlie COPD [34]. Since oxidative stress contributes to cellular ageing [35] as well as to COPD pathogenesis [17], we speculate that oxidative stress might explain the shared features of altered differentiation between MSCs from COPD patients and aged MSCs. This hypothesis is supported by observations in aged mice MSCs, that display decreased antioxidant power despite increases in proteins involved in antioxidant defence [36], which resembles observations made in COPD patients who have decreased antioxidant capacity [37], despite increased Nrf2 expression [38]. Concordantly, we observed lower expression of NQO1 and SCAL1 in MSCs from COPD patients, suggesting a lower antioxidant response upon induction of the Nrf2-ARE pathway. We found no differences in HMOX1 and GPX2 expression between groups, potentially explained by the role of other signalling pathways (c-Met and p63, resp) [39,40] in induction of these genes, whereas NQO1 and SCAL1 are thought to be more selective representatives of the Nrf2-ARE pathway [41,42]. Whether decreased mRNA expression of Nrf2-ARE target genes also results in decreased antioxidant activity needs further
elucidation before making more definite statements on this issue.

We have used MSCs from patients with severe to very severe COPD, and compared these to MSCs from non-COPD controls. MSCs from the control group were obtained from donors from whom sufficient MSCs were expanded during initial cultures, thus allowing storage of excess MSCs. We cannot rule out that this created a selection bias in the control group, in favour of better MSC proliferation and potentially even function, however such differences were not observed. We successfully prioritized on age-matching of both groups, but were unable to correct for smoking history, as all COPD patients were ex-smokers versus a majority of non- or never smokers in the control group. Whereas our data are unlikely affected by acute effects of CS on BM-MSCs (all COPD donors had quit smoking for at least six months before enrolment), we cannot exclude that we assessed effects on MSCs due to chronic CS exposure in the past. Effects of chronic CS exposure on MSCs has only been investigated to a limited extend in animal models, and to our knowledge this has not yet been investigated in human MSCs. Our study was not designed to address this question and therefore we cannot formally draw conclusions in this respect. However, taking into account the differences between the COPD and non-COPD group regarding smoking history, our data do not confirm previous results showing for instance detrimental effects of nicotine on proliferation and migration of MSCs [43].

Since Le Blanc’s report in 2004 describing remission of severe graft versus host disease after MSC infusion [44], much attention has been paid to the clinical application of MSCs in a variety of diseases, including lung diseases. Besides promising effects of MSCs on inflammation and regeneration, the interest in MSC-based cell therapy is attributable to the relatively easy method to obtain and expand MSCs and to their low-immunogenic status. These properties make MSCs interesting candidates for (commercial) cell-therapy programs. However, although allogeneic MSCs did not appear to induce immune responses in immunocompromised recipients, their application in immune competent recipients might not be ideal, as allogeneic MSCs were shown to elicit alloimmune responses in immune-competent recipients [45], which moreover appeared to have detrimental effects on MSC function [46]. This underlines the importance of evaluating the treatment potential of autologous MSCs. The data provided by the current study support the implementation of autologous MSCs as a cell-based therapy for patients with chronic lung disease in future clinical trials.

In conclusion, we observed that the (immuno)phenotype and function of MSCs from patients with COPD is preserved, compared to their healthy counterparts. This finding is important in light of the potential clinical use of autologous MSCs to treat COPD patients. However, we did observe differences in differentiation potential and in activation of the Nrf2-antioxidant response element pathway that might link systemic manifestations of COPD to increased cellular ageing of MSCs.
ACKNOWLEDGEMENTS

The authors thank Renate Verhoosel and Jasmijn Schrumpf for assisting in cell culture work and performing part of the differentiation assays, Annemarie van Schadewijk for performing the PCR analysis, Bram van der Linden for performing the ELISAs (all from department of Pulmonology, LUMC, the Netherlands), the Center for Stem Cell Therapy for providing initial MSC cultures and collecting the FACS data and proliferation curves (LUMC, the Netherlands), and Ron Wolterbeek for assisting in the statistical analysis (department of Medical Statistics, LUMC, the Netherlands).

FUNDING

This study was supported in part by a grant from the Lung Foundation Netherlands (grant #6.1.14.009).

The online supplementary information can be accessed via: http://openres.ersjournals.com/content/erjor/suppl/2016/06/28/2.2.00045-2015.DC2/ERJOR-00045-2015_supplementary_data.pdf
LIST OF ABBREVIATIONS

ADM1  adrenomedullin
AREG  amphiregulin
BM-MSCs  bone marrow-derived MSC
CCDN1  cyclin D1
CCL20  chemokine (C-C motif) ligand 20
CD    cluster of differentiation
CM    conditioned medium
COPD  chronic obstructive pulmonary disease
CSE   cigarette smoke extract
CXCL8  chemokine (C-X-C motif) ligand 8
ECIS  electric cell-substrate impedance sensing
EF    electric fence
EGF(R) epidermal growth factor (receptor)
FEV$_1$ forced expiratory volume in 1 second
FGF   fibroblast growth factor
GPX2  glutathion peroxidase 2
HBEGF heparin binding EGF-like growth factor
HGF   hepatocyte growth factor
HMOX1 heme oxygenase 1
IL    interleukin
LG-DMEM low glucose Dulbecco's modified eagle medium
MSC   mesenchymal stromal cell
MSC-CM$^\text{CTRL}$ MSC-conditioned medium from unstimulated MSCs
MSC-CM$^\text{STIM}$ MSC-conditioned medium from TNF-α/IL-1β stimulated MSCs
Nrf2-ARE nuclear factor (erythroid derived 2)-like 2 antioxidant response element
NQO1  NAD(P)H:quinone reductase 1
PDGFA  platelet derived growth factor subunit A
PDT   population doubling time
SCAL1  smoke and cancer-associated IncRNA-1 (SCAL1)
SF    serum free
SFN   sulforaphane
TGFA  transforming growth factor-α
TNF-α  tumor necrosis factor-α
TSG6  tumor necrosis factor-inducible gene 6
VEGF  vascular endothelial growth factor

FUNCTIONAL CHARACTERIZATION OF BM-MSCs FROM COPD PATIENTS | 79
REFERENCE LIST


### SUPPLEMENTARY TABLE S1. qPCR primer sequences

<table>
<thead>
<tr>
<th>Gene</th>
<th>Primer sequence forward</th>
<th>Primer sequence reverse</th>
</tr>
</thead>
<tbody>
<tr>
<td>ATP5B</td>
<td>5’-TCACCCAGGCTGGTTCAAGA-3’</td>
<td>5’-AGTGCCAGGCTGGCTGAT-3’</td>
</tr>
<tr>
<td>B2M</td>
<td>5’-GATCGAGACATGTAAGCAGC-3’</td>
<td>5’-TCAAGAACTGGGACGACGC-3’</td>
</tr>
<tr>
<td>RPL13A</td>
<td>5’-AAAGGTGGTGTGTCGACTGCTG-3’</td>
<td>5’-CGGGAAAGGTTGTTGTCTCATCC-3’</td>
</tr>
<tr>
<td>RPS29</td>
<td>5’-GCACGTGCTGAGACAGCAAGATG-3’</td>
<td>5’-ATAGGCACTGGAACGAAAGA-3’</td>
</tr>
<tr>
<td>ADM1</td>
<td>5’-ATGAAGCTGGTTCCGTCG-3’</td>
<td>5’-GACATGCCAGTTCCTCTCTT-3’</td>
</tr>
<tr>
<td>AREG</td>
<td>5’-GCTGGTCTGCTGCTCTTGG-3’</td>
<td>5’-AGGGTGCTGTAATCCAA-3’</td>
</tr>
<tr>
<td>B2M</td>
<td>5’-AAAGGTGGTGTGTCGACTGCTG-3’</td>
<td>5’-CGGGAAAGGTTGTTGTCTCATCC-3’</td>
</tr>
<tr>
<td>CDKN1</td>
<td>5’-GAATGGGATGGTACGCTG-3’</td>
<td>5’-CTGGCTAGGCTTGCCCAT-3’</td>
</tr>
<tr>
<td>CCL20</td>
<td>5’-GCAAGCAACTTTGACTGCTG-3’</td>
<td>5’-TGGGCTATGTTCCCTTCT-3’</td>
</tr>
<tr>
<td>CXCL12-1</td>
<td>5’-CTACAGATGCCCATGGCCAT-3’</td>
<td>5’-GTGGTGCTTAAGCCGAAAGTCC-3’</td>
</tr>
<tr>
<td>CXCL12-2</td>
<td>5’-GTAGGCCGCGCTGAAGAACA-3’</td>
<td>5’-GCTGCTGACCTCCTACAT-3’</td>
</tr>
<tr>
<td>EGF</td>
<td>5’-TGCAAGAGGATGCGGCTA-3’</td>
<td>5’-CAAGATGACACATGGGACGAC-3’</td>
</tr>
<tr>
<td>FGF2</td>
<td>5’-TGGCTATGGAAGAAGTGAAGA-3’</td>
<td>5’-TCAATGCTTTAAAAAGAAGAC-3’</td>
</tr>
<tr>
<td>FGF7</td>
<td>5’-TCTTGGCAACTTTGCTCTTAC-3’</td>
<td>5’-CAAGGCTGGAAACAGGACATC-3’</td>
</tr>
<tr>
<td>GPX2</td>
<td>5’-GAATGGGGAGAGACAGC-3’</td>
<td>5’-CCCGCCCTATGAGGAAACTCC-3’</td>
</tr>
<tr>
<td>HBEGF</td>
<td>5’-TGGAACCTTTTGAGAAGTCACTTATTCC-3’</td>
<td>5’-GCTGCTCTCTGTGTGTGTG-3’</td>
</tr>
<tr>
<td>HGF</td>
<td>5’-TCCAGAGGTGCTACAGAAGTA-3’</td>
<td>5’-CCATGCTAGTCTGACAT-3’</td>
</tr>
<tr>
<td>HMOX1</td>
<td>5’-AACCTTGAACAACGATAGTCTGCGA-3’</td>
<td>5’-ATGGTGCAACGGCAGGACAC-3’</td>
</tr>
<tr>
<td>IL6</td>
<td>5’-CAGACCTGTGCAAGTGAAGTACA-3’</td>
<td>5’-GATGAAGTTGCAATGCAAGAC-3’</td>
</tr>
<tr>
<td>CXCL8</td>
<td>5’-CAGCTGCTCTGTTTCTGCTG-3’</td>
<td>5’-ACCTCCACACACCCTCTGC-3’</td>
</tr>
<tr>
<td>NQO1</td>
<td>5’-GAAAGCAGCGCTGATTGGTTCG-3’</td>
<td>5’-GGATACATGAGATGGCGAGG-3’</td>
</tr>
<tr>
<td>PDGFA</td>
<td>5’-CACACCCAGCGAGCTCA-3’</td>
<td>5’-CCTGACCGTGAATTTGTTTG-3’</td>
</tr>
<tr>
<td>SCAL1</td>
<td>5’-GGCATTACCACTGAGGG-3’</td>
<td>5’-TACCCCTATCTAGCAGC-3’</td>
</tr>
<tr>
<td>TGFA</td>
<td>5’-AGGTCCGAAAAACTGTCTGAGG-3’</td>
<td>5’-AGCAAGAAAGTTGCTTCTG-3’</td>
</tr>
<tr>
<td>TSG6</td>
<td>5’-AGGATTTTGTGGGACGCCTCT-3’</td>
<td>5’-TGATTGGCCAGACCCGGTCTG-3’</td>
</tr>
<tr>
<td>VEGF</td>
<td>5’-CGAGGGGCTTGAGTGTG-3’</td>
<td>5’-AGGTGAGGTTGATCCGCCATA-3’</td>
</tr>
</tbody>
</table>
Figure S1. mRNA expression of immune mediators and growth factors in response to proinflammatory cytokines. mRNA expression upon stimulation of MSCs with TNF-α and IL-1β, calculated as fold change compared to mRNA expression in unstimulated MSCs from the same donor (at t=6 hours). Box whiskers represent median, interquartile range and minimum and maximum values. * = p < 0.05 for n = 9 per group.